Schernthaner, Guntram
Schernthaner-Reiter, Marie Helene
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 30 August 2017
Accepted: 29 November 2017
First Online: 7 February 2018
Duality of interest
: GS has served on global, European Union and national advisory board meetings of Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Jansen, NovoNordisk, Sanofi-Aventis, Servier and Takeda. He has received honoraria for lectures for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Jansen, NovoNordisk and Takeda. MHS-R has served on an advisory board for Boehringer Ingelheim and as a consultant for Novartis.